Topline results that were recently released from Sydnexis’s phase 3 Study of Atropine for the Reduction of Myopia Progression ...

Sydnexis Announces Topline Pivotal Data from Phase 3 STAR Trial of SYD-101 for Patients with Pediatric Progressive Myopia Presented at AMCP Nexus 2025 ...

While the trial met its primary endpoint, the FDA stated in its letter that the application could not be approved in its current form.

UAB School of Optometry professor is joining a national network study to research myopia prevention in children. Myopia, ...